Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Ms. Sandra  Pennell

Senior Vice President of Finance and Principal Financial & Accounting Officer

Dr. Johnny  John M.D.

Senior Vice President of Clinical Operations & Medical Affairs

Dr. Martha S. Rook Ph.D.

Chief Operating Officer

Mr. David  Hoffman

General Counsel, Corporate Secretary & Chief Compliance Officer

Dr. Vojislav  Vukovic M.D., Ph.D.

Chief Medical Officer

Mr. Gerard J. Michel MBA, MS

Chief Executive Officer & Director

Delcath Systems, Inc.

Delcath Systems, Inc. 経営体制

経営情報